[
  {
    "ts": null,
    "headline": "Buying These Dirt-Cheap Stocks Could Be a Brilliant Move",
    "summary": "Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move.  David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune.  It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.",
    "url": "https://finnhub.io/api/news?id=145f8054377ae13b981df5c7c8e02898a0a450f33f294b1277a55883d9cda3ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742640240,
      "headline": "Buying These Dirt-Cheap Stocks Could Be a Brilliant Move",
      "id": 133325241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move.  David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune.  It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.",
      "url": "https://finnhub.io/api/news?id=145f8054377ae13b981df5c7c8e02898a0a450f33f294b1277a55883d9cda3ea"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Bulls Need To Check Out Its Graham P/E",
    "summary": "Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher due to bleak growth and debt levels.",
    "url": "https://finnhub.io/api/news?id=8a0c54e4f97debb060c87707e4831f46aeca09e50630f1da604dc8e1628afd33",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742623351,
      "headline": "Pfizer: Bulls Need To Check Out Its Graham P/E",
      "id": 133318036,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440981/image_1292440981.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher due to bleak growth and debt levels.",
      "url": "https://finnhub.io/api/news?id=8a0c54e4f97debb060c87707e4831f46aeca09e50630f1da604dc8e1628afd33"
    }
  },
  {
    "ts": null,
    "headline": "Looking For Yields: Pfizer, Spire, And TriCo Bancshares Are Consistent Moneymakers",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Pfizer, Spire, and TriCo Bancshares have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of around 3% to 6%. Pfizer Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. Don't Miss: Maker of the $60,000 foldab",
    "url": "https://finnhub.io/api/news?id=fdf1824a9b603143a6e4d23719d03619cd00b7ddc702df994f5bbc8a578ce514",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742605219,
      "headline": "Looking For Yields: Pfizer, Spire, And TriCo Bancshares Are Consistent Moneymakers",
      "id": 133325243,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Pfizer, Spire, and TriCo Bancshares have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of around 3% to 6%. Pfizer Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. Don't Miss: Maker of the $60,000 foldab",
      "url": "https://finnhub.io/api/news?id=fdf1824a9b603143a6e4d23719d03619cd00b7ddc702df994f5bbc8a578ce514"
    }
  }
]